OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma
Reuters
Oct 10, 2025
<a href="https://laohu8.com/S/OSTX">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma
OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p < 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.